Damora Therapeutics Inc. (DMRA) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Damora Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Pharmaceutical Preparations
Price
$21.61
−1.59% today
Market cap
$1.4B
Overall quality
52/100
Kronos AI 30-day
+10.7%
8 of 8 simulated paths end higher
Damora Therapeutics Inc. (DMRA) is a Health Care company in Biotechnology: Pharmaceutical Preparations, worth $1.4B. It trades at $21.61, down 1.59% today. Its overall quality score is 52 out of 100, ranked against the whole US market. 7 analysts' average target of $46.67 implies +116.0% from today's price. Kronos AI's 30-day forecast is +10.7% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $46.67 |
| Low – high | $40.00 – $60.00 |
| Analysts | 7 |
| Upside to average | +116.0% |
Kronos AI 30-day forecast
| Expected close | $24.31 (+10.7%) |
| Likely range | +6.8% … +16.0% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 37 |
| Solvency | 89 |
| Growth | 30 |
| Overall | 52 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Pharmaceutical Preparations
For information only, not investment advice. Prices updated: 2026-10-29.